Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label study to investigate the safety, tolerability, and exposure of single ascending doses of the antisense oligonucleotide STK-002 in patients with autosomal dominant optic atrophy

Next Previous
Trial Profile

An open-label study to investigate the safety, tolerability, and exposure of single ascending doses of the antisense oligonucleotide STK-002 in patients with autosomal dominant optic atrophy

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STK 002 (Primary)
  • Indications Optic atrophy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms OSPREY
  • Sponsors Stoke Therapeutics

Most Recent Events

  • 11 Feb 2026 According to Stoke Therapeutics media release,The OSPREY study is actively recruiting in the United Kingdom and Germany. Additional European sites are expected to activate in the coming months.
  • 11 Feb 2026 According to Stoke Therapeutics media release, Dose escalation of the first four cohorts will continue through 2026 and early 2027, pending safety and tolerability assessments. Data from the OSPREY study will help to inform potential future development of STK-002.
  • 11 Feb 2026 According to Stoke Therapeutics media release, company announced that the first patient has been dosed in the Phase 1 OSPREY study of STK-002

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top